NCT01184560 is a NA clinical trial of Sibutramine in Obesity, sponsored by Gachon University Gil Medical Center.

Who is sponsoring NCT01184560?

NCT01184560 is sponsored by Gachon University Gil Medical Center.

What drugs are being tested in NCT01184560?

Interventions in NCT01184560: Sibutramine, Orlistat.

Is NCT01184560 still recruiting?

NCT01184560 is currently completed. Last updated 18 August 2010.

Last reviewed 2010-08-18 · How we verify

NCT01184560

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Double-blind, Placebo-controlled, Investigator-initiated Study to Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine

Completed NA Last updated 18 August 2010

What this trial tests

NA trial testing Sibutramine in Obesity in 174 participants. Completed in 1 July 2010.

Timeline

1 February 2010

Primary endpoint
1 July 2010

1 July 2010

Quick facts

Lead sponsor	Gachon University Gil Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	174
Start date	1 February 2010
Primary completion	1 July 2010
Estimated completion	1 July 2010
Sites	1 location across South Korea

Drugs / interventions tested

Sibutramine (SIBUTRAMINE) — full drug profile →
Orlistat — full drug profile →

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

Gachon University Gil Medical Center

Who can join

Adults 18 to 50, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Weight
Time frame: with in 18weeks
Weight
BMI(Body Mass Index)
Time frame: with in 18weeks
BMI(Body Mass Index)
waist circumference
Time frame: with in 18weeks
waist circumference
blood pressure
Time frame: with in 18weeks
blood pressure
fat mass
Time frame: with in 18weeks
fat mass
visceral fat mass improvement
Time frame: with in 18weeks
visceral fat mass improvement

Sponsor's own description

The purpose of this study, conducted academic Pilot research purposes, this is not clear as to permit. when orlistat to sibutramine merge if there are additional effects of BMI and group, which has an attribute that is greater for the combined effect is to analyze. * Study phase: Investigator-initiated clinical study (Pilot study) * Method of blinding: Double-blind * Control: Placebo-controlled * Assignment method: Randomization (Sibutramine monotherapy group: Orlistat and Sibutramine combination group = 1 : 1) * Studied disease: Obesity * Study population: Subjects eligible for inclusion/exclusion criteria * Dosing period: Total 18 weeks Run-in period (2 weeks), dosing period (12 weeks) and post-dosing observation period (4 weeks)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of the G-protein β3 subunit 825T allele on the change of body adiposity in obese female.
Hwang IC, Kim KK, Ahn HY, Suh HS, et al · · 2013 · cited 11× · PMID 23061407 · DOI 10.1111/dom.12023

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Gachon University Gil Medical Center trials

Trials by the same sponsor.

NCT07147114 — Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Pati · Phase 4 · recruiting
NCT05708157 — Concomitant Intranasal Antihistamine and Corticosteroid in Stepwise Treatment Strategy for Allergic Rhinitis · unknown
NCT06559202 — Inguinal and Axillary LN Size Distribution · completed
NCT04259918 — Effect of Alveolar Recruitment Maneuver on Postoperative Pain · NA · unknown
NCT04238351 — Transnasal Humidified Rapid Insufflation System for Intubation · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01184560 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gachon University Gil Medical Center
Last refreshed: 18 August 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01184560.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing